by Diap G, Boulet P, Andrieux-Meyer I, Bompart F. VIH Hépatites virales Santé sexuelle AFRAVIH 2020, 1095-1100.
Summary: The high price of direct acting antivirals (DAAs) against hepatitis C virus (HCV) is a major obstacle to the implementation of the diagnostic and treatment policies necessary to eradicate HCV infection globally within the timeline fixed by WHO. Recent drops in DAA prices are very unevenly distributed between countries and exclude most low- and middle-income countries that are too rich to benefit from voluntary license agreements, but are not able to finance DAAs at the price imposed by the patent holders. A competitive generic market to drive down DAA prices and mechanisms to obtain drugs at affordable prices as part of a determined hepatitis C elimination strategy are needed.
